Search - tctmd.com

Displaying 141 - 160 of 480

Sort: Relevancy | Date

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presentation TCT 2019

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presenter: C. Michael Gibson

September 27, 2019

Presentation TCT 2019

Endovascular Renal Sympathetic Denervation to Improve Heart Failure With Reduced Ejection Fraction: The IMPROVE HF-I Study

Presenter: Joost Daemen

September 27, 2019

Presentation TCT 2019

Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator in Patients with HFrEF and HFpEF: The AFR-PRELIEVE Trial

Presenter: Felix Mahfoud

September 27, 2019

Presentation TCT 2019

Epicardial LAAC to Reduce Atrial Fibrillation: AMAZE Rationale and Status

Presenter: DJ Lakkireddy

September 26, 2019

Presentation TCT 2019

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Presenter: Stephan Windecker

September 26, 2019

Presentation TCT 2019

Diagnostic Accuracy of Diastolic Pressure Ratio (dPR) using a Fiber-Optic Microcatheter

Presenter: Matthew Price

September 26, 2019

Presentation TCT 2019

Antithrombotic Therapy in PCI Patients With Atrial Fibrillation

Presenter: Marco Valgimigli

September 25, 2019

Presentation

Antithrombotic Therapy and CV Outcomes After TAVR in A-fib Patients

August 20, 2019

Presentation TVT 2019

Impact of Pre-Existing Atrial Fibrillation on Clinical Outcomes in Patients Who Underwent Balloon-Expandable Transcatheter Aortic Valve Replacement

Presenter: Hyungdon Kook

June 14, 2019

Presentation TVT 2019

Operator and Institutional Requirements for LAA Occlusion for Non-Valvular Atrial Fibrillation

Presenter: Hemal Gada

June 14, 2019

Presentation TVT 2019

Critical Appraisal of the Advantages and Limitations of Warfarin, NOACs, and Ablation in Patients With Non-Valvular Atrial Fibrillation

Presenter: DJ Lakkireddy

June 13, 2019

Presentation ARCH 2019

A Glimpse at Boston Scientific’s Structural Heart Therapies PortfolioAdvanced Revascularization Chapter XII

Presenter: David G. Rizik

April 11, 2019

Presentation ARCH 2019

Case Presentation: Atrial Fibrillation

Presenter: Curtis M. Steyers III

April 10, 2019

Presentation ARCH 2019

Practical Education: Tricks and Tools to Facilitate AF Ablation

Presenter: Sandeep Gautam

April 10, 2019

Presentation ARCH 2019

CABANA What Did We Learn? How Can We Do Better?

Presenter: Marye J. Gleva

April 10, 2019

Presentation ARCH 2019

Persistent AF: Lessons Learned from 30 years of Surgical Experience

Presenter: Ralph J. Damiano

April 10, 2019

Presentation ARCH 2019

Innovation in AF Ablation: Better Methods / Techniques for Successful Ablation

Presenter: Andrea Natale

April 10, 2019

Presentation SIF 2019

Pharmacologic Strategies for Managing Patients with Atrial Fibrillation Undergoing Coronary Intervention

Presenter: Michael A. Kutcher

March 28, 2019

Presentation ACC 2019

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial

Presenter: Renato Lopes

March 18, 2019

Presentation

Continued vs Interrupted Oral Anticoagulation During Transfemoral TAVR and Impact of Postop Anticoagulant Management in A-fib Patients

January 09, 2019

Advertisement

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Endovascular Renal Sympathetic Denervation to Improve Heart Failure With Reduced Ejection Fraction: The IMPROVE HF-I Study

Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator in Patients with HFrEF and HFpEF: The AFR-PRELIEVE Trial

Epicardial LAAC to Reduce Atrial Fibrillation: AMAZE Rationale and Status

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Diagnostic Accuracy of Diastolic Pressure Ratio (dPR) using a Fiber-Optic Microcatheter

Antithrombotic Therapy in PCI Patients With Atrial Fibrillation

Antithrombotic Therapy and CV Outcomes After TAVR in A-fib Patients

Impact of Pre-Existing Atrial Fibrillation on Clinical Outcomes in Patients Who Underwent Balloon-Expandable Transcatheter Aortic Valve Replacement

Operator and Institutional Requirements for LAA Occlusion for Non-Valvular Atrial Fibrillation

Critical Appraisal of the Advantages and Limitations of Warfarin, NOACs, and Ablation in Patients With Non-Valvular Atrial Fibrillation

A Glimpse at Boston Scientific’s Structural Heart Therapies PortfolioAdvanced Revascularization Chapter XII

Case Presentation: Atrial Fibrillation

Practical Education: Tricks and Tools to Facilitate AF Ablation

CABANA What Did We Learn? How Can We Do Better?

Persistent AF: Lessons Learned from 30 years of Surgical Experience

Innovation in AF Ablation: Better Methods / Techniques for Successful Ablation

Pharmacologic Strategies for Managing Patients with Atrial Fibrillation Undergoing Coronary Intervention

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial

Continued vs Interrupted Oral Anticoagulation During Transfemoral TAVR and Impact of Postop Anticoagulant Management in A-fib Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content